| DAIICHI-SANKYO |
DAIICHI-SANKYO |
92%
|
The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited |
| HCRP |
HCRP |
90%
|
We continue to have non-cash royalty revenue as all royalties received for the three months ended March 31, 2026 and 2025 were required to be paid to HCRP |
| LINCOLN-PARK |
LINCOLN-PARK |
90%
|
The Company will issue 447,067 shares of Common Stock (the "Commitment Shares") to Lincoln Park as consideration for its commitment to purchase shares of Common Stock under the Purchase Agreement. |
| UTAH-AVENUE-LANDLORD |
UTAH-AVENUE-LANDLORD |
90%
|
the Company agreed to lease from the Utah Avenue Landlord two additional suites in an additional building on Utah Avenue |
| HARBOR-WAY-LANDLORD |
HARBOR-WAY-LANDLORD |
80%
|
the Company entered into a termination agreement with another landlord (the “Harbor Way Landlord”) in connection with the termination of that certain lease agreement |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from AZN graph: Reciprocal relationship from VXRT graph: irements relating to the organization… |
| AZN |
AstraZeneca PLC |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| COCP |
Cocrystal Pharma, Inc. |
72%
|
Reciprocal relationship from COCP graph: Reciprocal relationship from VXRT graph: ion, any success in preclinical testing we might observe for our COVID-19 vaccine candidates may not be predictive of… |
| COCP |
Cocrystal Pharma, Inc. |
72%
|
ion, any success in preclinical testing we might observe for our COVID-19 vaccine candidates may not be predictive of the results of later-stage human clinical trials. Factors such as efficacy, immun… |
| CSLLY |
CSL Limited |
72%
|
Reciprocal relationship from CSLLY graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from CSLLY graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from CSLL… |
| CSLLY |
CSL Limited |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| EBS |
Emergent BioSolutions Inc. |
72%
|
Reciprocal relationship from EBS graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from EBS graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from EBS grap… |
| EBS |
Emergent BioSolutions Inc. |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| INO |
Inovio Pharmaceuticals, Inc. |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| INO |
Inovio Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from INO graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from INO graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from INO grap… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from MRK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and d… |
| NVSEF |
Novartis AG |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
Reciprocal relationship from SGIOF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from VXRT graph: irements relating to the organiza… |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| SNYNF |
Sanofi |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VXRT graph: irements relating to the organiza… |
| SVA |
Sinovac Biotech Ltd. |
72%
|
irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and… |
| SVA |
Sinovac Biotech Ltd. |
72%
|
Reciprocal relationship from SVA graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and dru… |
